Page last updated: 2024-08-24

valsartan and Cardiovascular Diseases

valsartan has been researched along with Cardiovascular Diseases in 123 studies

Research

Studies (123)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (3.25)	18.2507
2000's	52 (42.28)	29.6817
2010's	59 (47.97)	24.3611
2020's	8 (6.50)	2.80

Authors

Authors	Studies
Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y	1
Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS	1
Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N	1
Anand, IS; Boytsov, SA; Claggett, B; Cleland, J; Comin-Colet, J; Desai, AS; Düngen, HD; Ge, J; Goncalvesova, E; Gong, J; Jhund, PS; Katova, T; Kerr Saraiva, JF; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Senni, M; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zannad, F; Zhou, J; Zile, MR	1
Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H	1
Claessen, B; Mehran, R; Nicolas, J	1
Califf, RM; Gray, AM; Holman, RR; Leal, J; Li, Y; Patel, R; Reed, SD; Rivero-Arias, O; Schulman, KA	1
Haynes, R; Judge, PK	1
Ferreira, JP; McCausland, FR; Packer, M; Patel, RB; Rossignol, P; Shah, SJ; Solomon, SD; Stockbridge, N; Ter Maaten, JM; Thompson, A; Vaduganathan, M; Zannad, F	1
Briasoulis, A; Kuno, T; Ueyama, H	1
Gervasini, G; Robles, NR	1
Gaikwad, AB; Malek, V	1
Bridgeman, MB; Dalal, KS	1
El-Ashmony, SM; Fatani, SH; Kamel, HF; Shamardl, HA	1
Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S	1
António, N; Campos, M; Cunha, A; Gamboa-Cruz, C; Milner, J; Reis, J	1
Aronow, WS; Khan, MH; Rochlani, Y; Yandrapalli, S	1
Eržen, B; Janić, M; Novaković, S; Šabovič, M; Škerl, P; Turk Veselič, M; Žorž, N	1
James, M; Manns, B	1
Goldstein, BA; Holman, RR; Pagidipati, NJ; Pencina, MJ; Phelan, M; Stuart, EA	1
Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR	1
Haslam, A; Prasad, V	1
Abraham, I; Bowles, J; Brié, H; Hermans, C; Lee, C; Macdonald, K; Piotrowski, K; Vancayzeele, S	1
Ruilope, LM; Salazar, J; Segura, J	1
Normile, D	1
Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K	1
Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D	1
Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC	1
Baigent, C; Haynes, R; Judge, P; Landray, MJ	1
Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN	1
Crikelair, N; Kandra, A; Palatini, P; Zappe, DH	1
Dulsat, C	1
Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L	1
Cohen-Solal, A; Hugon, J; Launay, JM; Mebazaa, A; Paquet, C; Vodovar, N	1
Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Preiss, D; Schulte, PJ; Thomas, L; Tuomilehto, J; Yates, T	1
Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A	1
Jacob, MS; Sabe, MA; Taylor, DO	1
Bellows, BK; Bress, AP; King, JB; Nelson, RE; Shah, RU	1
Bhadra, R; Ghosh, RK; Gupta, A; Tummala, R	1
Claggett, B; Desai, A; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR	1
Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL	1
Bethel, MA; Currie, G; Haffner, SM; Holman, RR; Holzhauer, B; McMurray, JJV	1
Galle, J	1
Fukuda, M	1
Araki, R; Ikeda, N; Inoue, T; Kanno, Y; Shoda, J; Sugahara, S; Suzuki, H; Takenaka, T	1
Dahlöf, B; Matsubara, H; Sawada, T; Takahashi, T; Yamada, H	1
Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J	1
Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A	1
Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G	1
Dong, YF; Fukuda, M; Kaneko, T; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakagata, N; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E	1
Dahlöf, B; Matsubara, H; Sawada, T; Yamada, H	1
Bailey, J; Black, HR; Samuel, R; Zappe, D	1
Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B	1
Yarows, SA	1
Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L	1
Nathan, DM	1
Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J	2
Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J	1
Dahlöf, B; Ikewaki, K; Mochizuki, S; Rosano, G; Shimizu, M; Tada, N; Taniguchi, I; Yoshida, H; Yoshimura, M	1
Scheen, AJ	1
Eto, T; Imai, Y; Imaizumi, T; Ito, S; Kikuchi, K; Kimura, G; Matsuoka, H; Ogihara, T; Rakugi, H; Saruta, T; Shimada, K; Shimamoto, K; Takishita, S; Ueshima, H	1
Fujita, M; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H	1
Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M	1
Abraham, I; Aerts, A; Brié, H; Hermans, C; Lee, C; MacDonald, K; Vancayzeele, S	1
Vértes, A	1
Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E	1
Abraham, I; Aerts, A; Brié, H; Coen, N; Hermans, C; Lee, C; Lins, R; Macdonald, K; Mecum, N; Shen, YM; Vancayzeele, S	1
Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H	1
Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H	1
Baker, TM; Brede, Y; Brown, RE; Falvey, H; Goh, J; Johnston, A	1
Sestito, A	1
Abe, S; Furusho, Y; Hamasaki, S; Ikeda, Y; Kajiya, S; Kihara, K; Lee, S; Minagoe, S; Miyata, M; Nakamura, S; Ohba, I; Sasaki, T; Tateishi, S; Tei, C; Torii, H	1
Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH	1
Volpe, M	1
Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T	1
Angeli, F; Reboldi, G; Verdecchia, P	2
Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H	1
Krum, H; Martin, J	1
Kim, S	1
Handrock, R; Schmieder, RE	1
Balazovjech, I; Jezek, T	1
Brunner, H; Ekman, S; Hansson, L; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, G; Platt, F; Schork, AM; Smith, B; Weber, M; Zanchetti, A	1
Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S	1
Liebson, PR	1
Gottlieb, SO; Hennekens, CH; Lowry, DR; Malinin, AI; O'Connor, CM; Sane, DC; Serebruany, VL; Webb, RL	1
Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Weber, M; Zanchetti, A	1
Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Weber, MA; Zanchetti, A	1
Chrysant, GS; Chrysant, SG	1
Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S	1
Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S	1
Zidek, W	1
Berk, BC; Bisognano, JD	1
Einecke, D	1
Ruilope, LM; Segura, J	1
Takeuchi, M; Yamagishi, S	1
Ambrosi, P; Andrejak, M; Drici, MD; Herpin, D; Pithois-Merli, I	1
Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F	1
Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H	1
Sica, DA	1
Ogihara, T; Rakugi, H	1
Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV	1
Benetos, A; Cattan, V; Labat, C; Lacolley, P; Louis, H; Mercier, N; Safar, ME	1
Delea, TE; Frech-Tamas, F; Moynahan, A; Oster, G; Taneja, C; Thomas, SK	1
Müller, U; Scholze, J	1
Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M	1
Cohn, JN; Duprez, DA; Florea, ND; Jones, K	1
Victor, RG	1
Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S	1
Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H	1
Anderson, RE; Califf, RM; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Thune, JJ; Velazquez, E; White, HD	1
McMurray, JJ	1
Burrell, LM; Johnston, CI	1
Julius, S; Mann, J	1
McInnes, GT	1
Julius, S	1
Devereux, RB	1
Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E	1
Ramahi, TM	1

Reviews

34 review(s) available for valsartan and Cardiovascular Diseases

Article	Year
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current hypertension reports, 2022, Volume: 24, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left	2022
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. The American journal of cardiology, 2020, 04-15, Volume: 125, Issue:8 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan	2020
Implications of Kidney Disease in the Cardiac Patient. Interventional cardiology clinics, 2020, Volume: 9, Issue:3 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Contrast Media; Drug Combinations; Factor Xa Inhibitors; Female; Humans; Male; Percutaneous Coronary Intervention; Prevalence; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valsartan	2020
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease. Current opinion in nephrology and hypertension, 2021, Volume: 30, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan	2021
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 03-02, Volume: 143, Issue:9 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Valsartan	2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction. The American journal of cardiology, 2021, 08-15, Volume: 153 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left	2021
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert opinion on investigational drugs, 2017, Volume: 26, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valsartan	2017
Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 90 Topics: Aminobutyrates; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Humans; Neprilysin; Renal Insufficiency, Chronic; Tetrazoles; Valsartan	2017
[Neprilysin inhibition and chronic kidney disease]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2017, Sep-28, Volume: 34, Issue:5 Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan	2017
Recent major advances in cardiovascular pharmacotherapy. European journal of clinical pharmacology, 2018, Volume: 74, Issue:7 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Humans; Hypercholesterolemia; Neprilysin; PCSK9 Inhibitors; Tetrazoles; Valsartan	2018
Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Therapeutic advances in cardiovascular disease, 2018, Volume: 12, Issue:8 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Female; Hemodynamics; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left	2018
Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Neprilysin; Neurotransmitter Agents; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan	2013
Neprilysin inhibition in chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:5 Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan	2015
Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies. Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:3 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan	2016
Reduction of proteinuria with angiotensin receptor blockers. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2008
Determining the most appropriate components for a composite clinical trial outcome. American heart journal, 2008, Volume: 156, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan	2008
Valsartan: more than a decade of experience. Drugs, 2009, Volume: 69, Issue:17 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan	2009
Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva cardioangiologica, 2009, Volume: 57, Issue:6 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2009
Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:1 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Fumarates; Humans; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2010
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vascular health and risk management, 2011, Volume: 7 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypertension; Program Evaluation; Risk Assessment; Risk Factors; Tetrazoles; Translational Research, Biomedical; Treatment Outcome; Valine; Valsartan	2011
Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan. European review for medical and pharmacological sciences, 2011, Volume: 15, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Patient Compliance; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2011
Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:8 Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan	2012
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacological research, 2002, Volume: 46, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2002
[Tendency and prospect of the development of new ARBs]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Humans; Losartan; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan	2002
Clinical experience with angiotensin receptor blockers with particular reference to valsartan. Journal of clinical hypertension (Greenwich, Conn.), 2004, Volume: 6, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Tetrazoles; Valine; Valsartan	2004
Hope in Life and Value of blood pressure control. Journal of hypertension, 2004, Volume: 22, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan	2004
[The best of clinical pharmacology in 2004]. Archives des maladies du coeur et des vaisseaux, 2005, Volume: 98 Spec No 1 Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Complications; Humans; Obesity; Tetrazoles; Valine; Valsartan	2005
[VALISH]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 6 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination; Evidence-Based Medicine; Humans; Hypertension; Japan; Prospective Studies; Systole; Tetrazoles; Valine; Valsartan	2006
Pathophysiology of target-organ disease: does angiotensin II remain the key? Journal of clinical hypertension (Greenwich, Conn.), 2007, Volume: 9, Issue:11 Suppl 4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2007
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs & aging, 1997, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	1997
Angiotensin II antagonism in clinical practice: experience with valsartan. Journal of cardiovascular pharmacology, 1999, Volume: 33 Suppl 1 Topics: Age Factors; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Drug Synergism; Humans; Kidney Diseases; Racial Groups; Sex Factors; Tetrazoles; Valine; Valsartan	1999
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology, 1999, Volume: 91 Suppl 1 Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan	1999
Therapeutic options in minimizing left ventricular hypertrophy. American heart journal, 2000, Volume: 139, Issue:1 Pt 2 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2000
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. Postgraduate medicine, 2001, Volume: 109, Issue:4 Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan	2001

Trials

47 trial(s) available for valsartan and Cardiovascular Diseases

Article	Year
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. The New England journal of medicine, 2021, 11-11, Volume: 385, Issue:20 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left	2021
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199 Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan	2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England journal of medicine, 2019, 10-24, Volume: 381, Issue:17 Topics: Aged; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Neprilysin; Quality of Life; Sex Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan	2019
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes care, 2020, Volume: 43, Issue:10 Topics: Adult; Age of Onset; Aged; Benchmarking; Cardiometabolic Risk Factors; Cardiovascular Diseases; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Mortality; Prediabetic State; Primary Prevention; Quality of Life; Quality-Adjusted Life Years; United Kingdom; United States; Valsartan	2020
Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study. International angiology : a journal of the International Union of Angiology, 2018, Volume: 37, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Arteries; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Phenotype; Pilot Projects; Risk Factors; Slovenia; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Vasodilation	2018
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC. Heart failure, 2019, Volume: 7, Issue:6 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases	2019
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11 Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. European journal of preventive cardiology, 2015, Volume: 22, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan	2015
Time of administration important? Morning versus evening dosing of valsartan. Journal of hypertension, 2015, Volume: 33, Issue:2 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Lisinopril; Male; Middle Aged; Risk Factors; Treatment Outcome; Valsartan	2015
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. The American journal of medicine, 2015, Volume: 128, Issue:3 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism	2015
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. Archives of Iranian medicine, 2015, Volume: 18, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Urban Population; Valsartan	2015
A new class of drugs for systolic heart failure: The PARADIGM-HF study. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:10 Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan	2015
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC. Heart failure, 2016, Volume: 4, Issue:10 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Case-Control Studies; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan	2016
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Valsartan	2017
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Female; Humans; Incidence; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Renal Dialysis; Tetrazoles; Valine; Valsartan	2008
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. Journal of human hypertension, 2009, Volume: 23, Issue:3 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Japan; Male; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2009
Determining the most appropriate components for a composite clinical trial outcome. American heart journal, 2008, Volume: 156, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan	2008
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC. Cardiovascular imaging, 2008, Volume: 1, Issue:5 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling	2008
Valsartan for prevention of recurrent atrial fibrillation. The New England journal of medicine, 2009, Apr-16, Volume: 360, Issue:16 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan	2009
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. European heart journal, 2009, Volume: 30, Issue:20 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Prospective Studies; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2009
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovascular therapeutics, 2010, Volume: 28, Issue:2 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan	2010
Effect of nateglinide on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan	2010
Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan	2010
Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. Journal of hypertension, 2010, Volume: 28, Issue:6 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Middle Aged; Risk Reduction Behavior; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2010
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide]. Revue medicale de Liege, 2010, Volume: 65, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan	2010
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:2 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Medical History Taking; Patient Selection; Proportional Hazards Models; Reference Values; Stroke; Systole; Tetrazoles; Valine; Valsartan	2010
Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:1 Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan	2011
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. Journal of human hypertension, 2012, Volume: 26, Issue:11 Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2012
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study. Clinical and experimental hypertension (New York, N.Y. : 1993), 2012, Volume: 34, Issue:2 Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan	2012
Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:4 Topics: Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Apolipoproteins E; Biomarkers; Cardiovascular Diseases; Disease Models, Animal; Female; Fibrinolysis; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2012
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. Journal of hypertension, 2012, Volume: 30, Issue:11 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2012
An additional LDL-lowering effect of amlodipine; not only an antihypertensive? Clinical and experimental hypertension (New York, N.Y. : 1993), 2013, Volume: 35, Issue:6 Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Essential Hypertension; Female; Humans; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Tetrazoles; Triglycerides; Valine; Valsartan	2013
[Control of systolic blood pressure in the VALUE trial after 12 months]. Deutsche medizinische Wochenschrift (1946), 2003, Mar-07, Volume: 128, Issue:10 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Europe; Female; Germany; Humans; Hypertension; Male; Middle Aged; Prognosis; Reference Standards; Risk Factors; Tetrazoles; Valine; Valsartan	2003
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial in Slovakia. Bratislavske lekarske listy, 2003, Volume: 104, Issue:1 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk Factors; Slovakia; Tetrazoles; Valine; Valsartan	2003
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. American journal of hypertension, 2003, Volume: 16, Issue:7 Topics: Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Double-Blind Method; Drug Utilization; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk; Tetrazoles; Valine; Valsartan	2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diuretics; Double-Blind Method; Endpoint Determination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2004
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:4 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling	2004
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. The New England journal of medicine, 2004, Sep-23, Volume: 351, Issue:13 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan	2004
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct Circulation, 2005, Nov-29, Volume: 112, Issue:22 Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American journal of hypertension, 2006, Volume: 19, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2006
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:3 Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan	2007
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. Journal of the American College of Cardiology, 2007, Aug-28, Volume: 50, Issue:9 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan	2007
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7 Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American heart journal, 2008, Volume: 155, Issue:4 Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Sex Factors; Smoking; Survivors; Tetrazoles; Valine; Valsartan	2008
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood pressure, 1998, Volume: 7, Issue:3 Topics: Aged; Amlodipine; Angiotensin II; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Prospective Studies; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	1998
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology, 1999, Volume: 91 Suppl 1 Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Tetrazoles; Valine; Valsartan	1999

Other Studies

44 other study(ies) available for valsartan and Cardiovascular Diseases

Article	Year
Combination cardiovascular drugs. Nursing, 2017, Volume: 47, Issue:8 Topics: Aminobutyrates; Amlodipine; Aspirin; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Nebivolol; Omeprazole; Perindopril; Tetrazoles; Valsartan	2017
Potential Cardiovascular and Renal Protective Effects of Vitamin D and Coenzyme Q The American journal of the medical sciences, 2017, Volume: 354, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Hypertension; Kidney Diseases; NG-Nitroarginine Methyl Ester; Rats; Rats, Wistar; Ubiquinone; Valsartan; Vitamin D; Vitamins	2017
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease. Circulation, 2018, 10-09, Volume: 138, Issue:15 Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Humans; Irbesartan; Neprilysin; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles; Valsartan	2018
An outcome model approach to transporting a randomized controlled trial results to a target population. Journal of the American Medical Informatics Association : JAMIA, 2019, 05-01, Volume: 26, Issue:5 Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan	2019
Confirmatory Trials for Drugs Approved on a Single Trial. Circulation. Cardiovascular quality and outcomes, 2019, Volume: 12, Issue:6 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Drug Approval; Drug Combinations; Eicosapentaenoic Acid; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Research Design; Tetrazoles; Treatment Outcome; Valsartan	2019
Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study). Archives of cardiovascular diseases, 2013, Volume: 106, Issue:3 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Belgium; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chi-Square Distribution; Comparative Effectiveness Research; Female; General Practice; Humans; Hypertension; Kidney Diseases; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2013
Japan. Tampered data cast shadow on drug trial. Science (New York, N.Y.), 2013, Jul-19, Volume: 341, Issue:6143 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomedical Research; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Japan; Scientific Misconduct; Tetrazoles; Valine; Valsartan	2013
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ (Clinical research ed.), 2013, Dec-09, Volume: 347 Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:5 Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2014
A report from the European Society of Cardiology Congress 2014 (August 30-September 3 - Barcelona, Spain). Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:9 Topics: Aminobutyrates; Benzaldehydes; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Diseases; Drug Combinations; Enalapril; Humans; Ivabradine; Oximes; Stents; Tetrazoles; Valsartan	2014
Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split? European heart journal, 2015, Apr-14, Volume: 36, Issue:15 Topics: Alzheimer Disease; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood-Brain Barrier; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Neprilysin; Tetrazoles; Valsartan	2015
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:8 Topics: Accelerometry; Actigraphy; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Cyclohexanes; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Regression Analysis; Risk Factors; Risk Reduction Behavior; Valsartan	2015
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC. Heart failure, 2016, Volume: 4, Issue:5 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Middle Aged; Neprilysin; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan	2016
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. Journal of the American Heart Association, 2017, 01-13, Volume: 6, Issue:1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan	2017
Can changing antihypertensive administration time alone reduce the risk for CVD in nondipper patients with CKD? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:1 Topics: Antihypertensive Agents; Cardiovascular Diseases; Chronotherapy; Follow-Up Studies; Humans; Hypertension; Incidence; Renal Insufficiency, Chronic; Risk Assessment; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2008
Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:3 Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Cardiovascular System; Drug Synergism; Drug Therapy, Combination; Fumarates; Gene Expression; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Receptor, Angiotensin, Type 1; Renin; RNA, Messenger; Superoxides; Tetrazoles; Tunica Intima; Valine; Valsartan	2009
Navigating the choices for diabetes prevention. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan	2010
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. The European journal of health economics : HEPAC : health economics in prevention and care, 2011, Volume: 12, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Female; Greece; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Markov Chains; Middle Aged; Models, Economic; Quality of Life; Sex Factors; Tetrazoles; Valine; Valsartan	2011
Determinants of masked hypertension in hypertensive patients treated in a primary care setting. Internal medicine journal, 2012, Volume: 42, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension	2012
[The significance of generic valsartan in the treatment of patients]. Lege artis medicinae : uj magyar orvosi hirmondo, 2011, Volume: 21, Issue:2 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2011
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011, Volume: 62, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling	2011
Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study. Archives of cardiovascular diseases, 2011, Volume: 104, Issue:8-9 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2011
Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. Journal of medical economics, 2012, Volume: 15, Issue:2 Topics: Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Substitution; Fees, Pharmaceutical; Humans; Hypertension; Insurance, Health, Reimbursement; Losartan; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Tetrazoles; United States; Valine; Valsartan	2012
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID). Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2 Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan	2013
Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2 Topics: Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan	2013
VALIANT and EUROPA. Preventive cardiology, 2004,Winter, Volume: 7, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. Journal of cardiovascular pharmacology, 2004, Volume: 43, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Platelets; Cardiovascular Diseases; Dual Specificity Phosphatase 2; Female; Flow Cytometry; Humans; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Protein Phosphatase 2; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Tetrazoles; Valine; Valsartan	2004
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan	2004
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Valine; Valsartan	2004
VALUE in hypertension treatment. Current hypertension reports, 2004, Volume: 6, Issue:6 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan	2004
[AT1 blocker or calcium antagonist in treatment of hypertension. What protects the heart better?]. MMW Fortschritte der Medizin, 2004, Jun-24, Volume: 146, Issue:26 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan	2004
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks]. Praxis, 2004, Oct-13, Volume: 93, Issue:42 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Valine; Valsartan	2004
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks]. Praxis, 2004, Oct-27, Volume: 93, Issue:44 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan	2004
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Medical hypotheses, 2005, Volume: 64, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan	2005
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology, 2006, Feb-21, Volume: 47, Issue:4 Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan	2006
The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Drug Administration Schedule; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan	2006
Sodium, arterial stiffness, and cardiovascular mortality in hypertensive rats. American journal of hypertension, 2007, Volume: 20, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Compliance; Disease Models, Animal; Hypertension; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan	2007
Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Jun-01, Volume: 64, Issue:11 Topics: Antihypertensive Agents; Cardiovascular Diseases; Delayed-Action Preparations; Female; Humans; Hypertension; Insurance Claim Review; Kidney Diseases; Lisinopril; Male; Metoprolol; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Tetrazoles; Valine; Valsartan	2007
[Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)]. MMW Fortschritte der Medizin, 2006, Oct-19, Volume: 148, Issue:42 Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Prospective Studies; Risk Factors; Tetrazoles; Valine; Valsartan	2006
New-onset diabetes, antihypertensive treatment, and outcome. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:3 Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Prognosis; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan	2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:1 Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008
[Risk oriented therapy of hypertension. Lowering blood pressure and risk]. MMW Fortschritte der Medizin, 2007, Nov-15, Volume: 149, Issue:46 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Hypertension; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan	2007
ACE inhibitors in cardiovascular disease--unbeatable? The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Research Design; Telmisartan; Tetrazoles; Valine; Valsartan	2008
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2 Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan	2001